In Vitro Evaluation Of Hemerus Apex™ Additive Solution For Preservation Of Cpda-1 Whole Blood As Compared To Cpda-1 Whole Blood Without Additive Solution
Posted Date: Sep 27, 2022
- Investigator: Jose Cancelas
- Specialties:
- Type of Study: Drug
Hemerus Medical, LLC is developing a new formulation of anticoagulant preservative that will yield similar or improved quality whole blood (WB) providing an extended shelf life to at least 42 days compared to the current 21-day product (Citrate Phosphate Dextrose [CPD] anticoagulant) or 35-day product (Citrate Phosphate Dextrose Adenine [CPDA-1] anticoagulant). The hypothesis is that reformulation of anticoagulant-preservative solution will provide longer shelf life for WB with acceptable red blood cell (RBC) quality, platelet function, and plasma factor stability over the conventional CPDA-1 anticoagulant.
Criteria:
Normal Healthy Blood Donors
Keywords:
Whole Blood Donation, Normal Healthy Blood Donors
For More Information:
Neeta Rugg
5136520104
neeta.rugg@uc.edu